TXMD - TherapeuticsMD Inc
IEX Last Trade
1.095
-0.065 -5.936%
Share volume: 0
Last Updated: Thu 26 Dec 2024 09:17:13 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.90%
PREVIOUS CLOSE
CHG
CHG%
$1.16
-0.07
-5.60%
View ratios
| Fiscal Date | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
| Report Date | 2022-05-16 | 2022-08-15 | 2022-11-14 | 2023-04-07 | 2023-05-15 | 2023-08-14 | 2023-11-14 | 2024-03-29 | |
| Assets | |||||||||
| Total Assets | 133.381 M | 146.202 M | 133.907 M | 90.458 M | 59.601 M | 53.689 M | 50.493 M | 43.309 M | |
| Current Assets | 84.424 M | 98.603 M | 87.478 M | 55.351 M | 24.735 M | 19.613 M | 17.441 M | 11.796 M | |
| Inventories | 8.967 M | 6.150 M | 6.701 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 9.660 M | 9.096 M | 10.290 M | 6.034 M | 5.446 M | 5.043 M | 4.570 M | 4.035 M | |
| Short Term Investments | 9.660 M | 9.096 M | 10.290 M | 6.034 M | 5.446 M | 5.043 M | 4.570 M | 4.035 M | |
| Total Receivables | 35.413 M | 45.804 M | 32.157 M | 0.000 | 2.041 M | 841.000 K | 2.705 M | 3.090 M | |
| Current Cash | 30.384 M | 26.303 M | 27.080 M | 38.067 M | 17.248 M | 13.729 M | 10.166 M | 4.327 M | |
| Total Non-current Assets | 48.957 M | 47.599 M | 46.429 M | 35.107 M | 34.866 M | 34.076 M | 33.052 M | 31.513 M | |
| Property Plant Equipment | 1.082 M | 710.000 K | 551.000 K | 78.000 K | 58.000 K | 39.000 K | 19.000 K | 0.000 | |
| Other Assets | 253.000 K | 254.000 K | 253.000 K | 20.506 M | 20.525 M | 20.042 M | 19.321 M | 18.542 M | |
| Intangible Assets | 39.547 M | 38.721 M | 37.876 M | 6.943 M | 6.877 M | 6.767 M | 6.657 M | 6.098 M | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 133.381 M | 146.202 M | 133.907 M | 90.458 M | 59.601 M | 53.689 M | 50.493 M | 43.309 M | |
| Total liabilities | 273.961 M | 172.268 M | 182.178 M | 55.315 M | 27.577 M | 22.492 M | 22.441 M | 14.022 M | |
| Total current liabilities | 264.835 M | 163.986 M | 174.071 M | 46.839 M | 19.336 M | 14.364 M | 14.512 M | 6.854 M | |
| Accounts Payable | 20.753 M | 13.978 M | 13.383 M | 2.162 M | 2.326 M | 1.508 M | 696.000 K | 27.000 K | |
| Other liabilities | 1.229 M | 554.000 K | 554.000 K | 1.107 M | 1.106 M | 1.189 M | 1.189 M | 636.000 K | |
| Current long term debt | 202.857 M | 90.780 M | 93.602 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 1.229 M | 554.000 K | 554.000 K | 1.107 M | 1.106 M | 1.189 M | 1.189 M | 636.000 K | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | -140.580 M | -26.066 M | -48.271 M | 35.143 M | 32.024 M | 31.197 M | 28.052 M | 29.287 M | |
| Common stock | 8.614 M | 8.750 M | 9.261 M | 9.487 M | 9.754 M | 10.219 M | 10.701 M | 11.090 M | |
| Retained earnings | -1.100 B | -988.100 M | -1.017 B | -939.363 M | -942.966 M | -945.380 M | -948.758 M | -949.641 M |